Floatz logo

Horse Anti-Thymocyte Globulin

Immunodeficiencies

New York Medical CollegePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Immunodeficiencies cohort.

Asset / SponsorPhaseRating
Evomela
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
Busulphan
University of California, San Francisco
Phase 2BB
Thiotepa
University of California, San Francisco
Phase 2BB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
HUMAN IMMUNOGLOBULINS
Grifols Therapeutics LLC
Phase 3B

View all 23 →

Same molecule, other indications

Horse Anti-Thymocyte Globulin is also rated in:

bone marrow failure syndromeDormant
B
Indicative ·
62 / 100
View asset →
Fanconi anemiaDormant
CCC
Indicative ·
54 / 100
View asset →
osteopetrosisDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →